Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837132 | 1.00 | TK1 (0.45) | TK1CTSKKCNN4ADRB2ADRB1 | |
| SCHEMBL29150824 | 0.87 | TK1 (0.48) | TK1CTSKKCNN4ADRB2ADRB1 | |
| SCHEMBL5829016 | 0.85 | TK1 (0.46) | TK1CTSKPOLBLMNAKMT2A | |
| SCHEMBL4925573 | 0.84 | TK1 (0.46) | TK1CTSKKIF11LMNAALDH1A1 | |
| SCHEMBL4926228 | 0.84 | TK1 (0.46) | TK1CTSKKIF11LMNAALDH1A1 | |
| SCHEMBL4191209 | 0.84 | TK1 (0.46) | TK1CTSKKIF11LMNAALDH1A1 | |
| SCHEMBL9173106 | 0.82 | TK1 (0.43) | TK1CTSKKCNN4ADRB2ADRB1 | |
| SCHEMBL10463726 | 0.82 | TK1 (0.43) | TK1CTSKKCNN4ADRB2ADRB1 | |
| SCHEMBL3954890 | 0.81 | TK1 (0.44) | TK1CTSKKIF11LMNAKMT2A | |
| SCHEMBL2131414 | 0.81 | TK1 (0.44) | TK1CTSKKIF11LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238826-B2 | Boronate esters | BIOCON LIMITED (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060040898-A1 | Novel boronate esters | BIOCON LIMITED (IN) | 2006-02-23 | — | — | US | disclosed |
| EP-0244364-A2 | Preparation of olefinic compounds | SANDOZ AG (CH) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040898-A1 | Novel boronate esters | HMGCR, BLVRB, COASY | TK1 1347/4885CTSK 1006/4885KCNN4 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.